Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance

Institut Paoli-Calmettes

Status: Not yet enrolling

Conditions: Hematologic Cancer

Treatments: Other: experimental:Acute leukemia/myelodysplastic or myeloproliferative disease

Study type: Interventional

Funder types: Other

Identifiers

NCT05602168

HEMATOBIO.02-IPC 2021-061

Details and patient eligibility

About

The main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with IT resistance through the constitution of a collection associating blood or marrow samples from patients with LA, MDS and MPS marrow samples from patients with LA, MDS and MPS at diagnosis, during treatment and at relapse and relapse and clinical annotations.

Full description

It is a collection of blood, marrow and oral epithelial cell samples taken longitudinally and oral epithelial cells taken longitudinally for each patient included, with each patient included, with the corresponding clinical data. An oral epithelial cell sample will be collected at inclusion from 2 swabs, which will allow extraction of DNA from healthy from healthy cells. During blood sampling necessary for care, an additional 40 ml of blood will be collected of 40 ml of blood will be collected in 10 tubes of 4 ml: 4 EDTA tubes, 4 heparinized heparinized tubes and 2 dry tubes. These additional collections will take place at the following times:

• At inclusion
• 7 days (+/- 2 days) after initiation of treatment
• 14 days (+/- 2 days) after initiation of therapy
• 21-42 days after initiation of therapy (early response assessment)
• In case of complete remission
• In case of relapse or progression During bone marrow punctures required for treatment, 6 ml of bone marrow bone marrow will be collected in 2 tubes of 3 ml: 1 EDTA tube and 1 heparinized tube.

heparinized tube. These additional collections will take place at the following times following times:

• At inclusion
• 21-42 days after initiation of treatment (assessment of early response) early response)
• In case of complete remission
• In case of relapse or progression Patients will be followed for up to 2 years after inclusion.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosis of acute leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) or myeloproliferative syndrome according to the WHO classification 2016,
2. Patient for whom a new line of therapy is initiated.
3. Patient older than 18 years of age.
4. Patient affiliated to the social security system or benefiting from such a system.
5. Signed consent to participate.

Exclusion criteria

1. Weight at inclusion < 50 kg
2. Participating in another clinical study that would cause the total amount of blood collection to exceed the and endanger the patient
3. Person in an emergency situation, adult under legal protection (guardianship, curatorship, etc.) protection (guardianship, curatorship or safeguard of justice), or unable to express his or her consent.
4. Impossibility to submit to the medical follow-up of the trial for geographical social or psychological reasons,
5. Pregnant or breastfeeding women

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

400 participants in 1 patient group

experimental:Acute leukemia/myelodysplastic or myeloproliferative disease

Experimental group

Description:

blood sampling, bone marrow aspirate, and buccal swab

Treatment:

Other: experimental:Acute leukemia/myelodysplastic or myeloproliferative disease